An Open-Label, Multicenter, First in Human, Phase 1 Dose Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Details
Age
Adult
Eligibility
expansion is limited to malignant pleural mesothelioma, gastric adenocarcinoma and colorectal adenocarcinoma
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Christopher Lieu, MD
Study ID
Protocol Number: 18-1672
More information available at ClinicalTrials.gov: NCT03715933
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers